Intelligent Bio Solutions Files 8-K
Ticker: INBS · Form: 8-K · Filed: Oct 30, 2025 · CIK: 1725430
Sentiment: neutral
Topics: financial-reporting, exhibits
TL;DR
IBSI filed an 8-K on 10/30/25 for financial statements and exhibits.
AI Summary
Intelligent Bio Solutions Inc. filed an 8-K on October 30, 2025, reporting on financial statements and exhibits. The company, formerly known as GBS Inc., is incorporated in Delaware and has its principal executive offices in New York City.
Why It Matters
This filing provides an update on the company's financial reporting and exhibits, which is crucial for investors to assess its current financial health and operational status.
Risk Assessment
Risk Level: low — This is a routine filing of financial statements and exhibits, not indicating any immediate operational or financial distress.
Key Players & Entities
- Intelligent Bio Solutions Inc. (company) — Registrant
- GBS Inc. (company) — Former company name
- October 30, 2025 (date) — Date of report
- New York (location) — Principal executive offices
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The filing indicates 'Financial Statements and Exhibits' are included, but the specific details of these documents are not provided in the provided text.
What is the significance of the former company names listed?
The former names, GBS Inc. and Glucose Biosensor Systems (Greater China) Holdings, Inc., indicate historical changes in the company's identity or structure.
When was Intelligent Bio Solutions Inc. incorporated?
The company is incorporated in Delaware, as stated in the filing.
What is the primary business address of Intelligent Bio Solutions Inc.?
The principal executive offices are located at 135 West 41st Street, 5th Floor, New York, NY 10036.
What is the Commission File Number for Intelligent Bio Solutions Inc.?
The Commission File Number is 001-39825.
Filing Stats: 524 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-10-30 17:15:46
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value INBS The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 35KB
- ex99-1.htm (EX-99.1) — 15KB
- 0001493152-25-020262.txt ( ) — 220KB
- inbs-20251030.xsd (EX-101.SCH) — 3KB
- inbs-20251030_lab.xml (EX-101.LAB) — 33KB
- inbs-20251030_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 30, 2025, Intelligent Bio Solutions Inc. (the "Company"), issued a press release (the "Press Release") announcing the addition of 33 new customer accounts during its fiscal first quarter for the period ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The foregoing disclosure is qualified in its entirety by the full text of the Press Release. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for the purpose of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference. Item 9.01 Financial Statements and Exhibits. No. Description 99.1 Press Release dated October 30, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 30, 2025 INTELLIGENT BIO SOLUTIONS INC. By: /s/ Spiro Sakiris Name: Spiro Sakiris Title: Chief Financial Officer